ArticleSignal transduction and targeted therapy2023

Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma.

Weiping Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.